Skip to main navigation

Our Science
Pipeline & Clinical Trials
- Pipeline
- Previous Clinical Trials
Investors & News
About Us
Contact

Event Details

Overview
News & Events
Stock Information
Financial Information
Governance
Investor Resources

Press Releases
Events
Presentations

Trevi Therapeutics, Inc. - 1Q 2024 Financial Results

May 7, 2024 from | 4:30 PM to 5:30 PM EDT

Investor Contact

drafts IR@trevitx.com

phone_iphone (203) 304-2499

Subscribe to our Email Alerts

Email Address Required

Privacy Policy
Consumer Health Data Privacy Policy
Terms of Use

Haduvio (nalbuphine ER) is an investigational therapy and not yet approved for use in any indication.

© 2026 Trevi Therapeutics, Inc. All Rights Reserved. Terms of Service.

Search Investors

Search this site